Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 5/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | RARB | P10826 | 1/20 | 0.43 |
| ▸ | RARG | P13631 | 1/20 | 0.43 |
| ▸ | TYR | P14679 | 1/20 | 0.43 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19240364 | 0.81 | HDAC1 (0.50) | HDAC1RAB9ANPC1LMNAMAPT | |
| SCHEMBL21503913 | 0.81 | ALDH1A1 (0.40) | HDAC1RAB9ANPC1LMNAMAPT | |
| SCHEMBL15131976 | 0.78 | SMN1; SMN2 (0.47) | RAB9ANPC1LMNAMAPTPOLB | |
| SCHEMBL18812047 | 0.77 | NR1H4 (0.41) | HDAC1RAB9ANPC1LMNAMAPT | |
| SCHEMBL13762029 | 0.77 | HDAC1 (0.67) | HDAC1RAB9ANPC1LMNAMAPT | |
| SCHEMBL24862750 | 0.76 | LMNA (0.35) | HDAC1LMNAHDAC3HDAC8HDAC6 | |
| SCHEMBL28160104 | 0.75 | LMNA (0.52) | HDAC1RAB9ANPC1LMNAMAPT | |
| SCHEMBL8779434 | 0.75 | HDAC1 (0.53) | HDAC1RAB9ANPC1LMNAMAPT | |
| SCHEMBL28232672 | 0.75 | HDAC1 (0.53) | HDAC1RAB9ANPC1LMNAMAPT | |
| SCHEMBL24862600 | 0.73 | HDAC1 (0.47) | HDAC1RAB9ANPC1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190040021-A1 | FUNCTIONALIZED 1,2,4,5-TETRAZINE COMPOUNDS FOR USE IN BIOORTHOGONAL COUPLING REACTIONS | THE GENERAL HOSPITAL CORPORATION | 2019-02-07 | — | — | US | disclosed |
| US-9902705-B2 | Functionalized 1,2,4,5-tetrazine compounds for use in bioorthogonal coupling reactions | THE GENERAL HOSPITAL CORPORATION (US) | 2018-02-27 | — | — | US | disclosed |
| EP-2744804-B1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN LA ROCHE (CH) | 2017-05-17 | — | — | EP | disclosed |
| WO-2013024078-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190040021-A1 | FUNCTIONALIZED 1,2,4,5-TETRAZINE COMPOUNDS FOR USE IN BIOORTHOGONAL COUPLING REACTIONS | TIE1, TTL, EPHA2 | HDAC1 2158/4885RAB9A 4257/4885NPC1 3803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.